Seiichiro Mitani

781 total citations
69 papers, 513 citations indexed

About

Seiichiro Mitani is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Seiichiro Mitani has authored 69 papers receiving a total of 513 indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Pulmonary and Respiratory Medicine, 49 papers in Oncology and 19 papers in Surgery. Recurrent topics in Seiichiro Mitani's work include Gastric Cancer Management and Outcomes (35 papers), Colorectal Cancer Treatments and Studies (26 papers) and Lung Cancer Treatments and Mutations (11 papers). Seiichiro Mitani is often cited by papers focused on Gastric Cancer Management and Outcomes (35 papers), Colorectal Cancer Treatments and Studies (26 papers) and Lung Cancer Treatments and Mutations (11 papers). Seiichiro Mitani collaborates with scholars based in Japan, United States and South Korea. Seiichiro Mitani's co-authors include Hisato Kawakami, Kei Muro, Shigenori Kadowaki, Yukiya Narita, Takashi Ura, Masashi Ando, Toshiki Masuishi, Kazunori Honda, Keiji Sugiyama and Hiroya Taniguchi and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Annals of Oncology.

In The Last Decade

Seiichiro Mitani

58 papers receiving 505 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Seiichiro Mitani Japan 11 258 195 102 87 72 69 513
Yukiya Narita Japan 14 374 1.4× 363 1.9× 101 1.0× 171 2.0× 71 1.0× 98 732
Guy de Laroche France 12 206 0.8× 199 1.0× 60 0.6× 127 1.5× 46 0.6× 43 519
Frédéric Fiteni France 14 346 1.3× 266 1.4× 108 1.1× 133 1.5× 31 0.4× 41 611
Danila Comandini Italy 11 269 1.0× 191 1.0× 31 0.3× 88 1.0× 39 0.5× 31 446
V.E.P.P. Lemmens Netherlands 13 498 1.9× 216 1.1× 62 0.6× 268 3.1× 70 1.0× 27 811
Olumide B. Gbolahan United States 18 312 1.2× 179 0.9× 63 0.6× 116 1.3× 68 0.9× 65 766
Jacopo Giuliani Italy 12 206 0.8× 194 1.0× 67 0.7× 65 0.7× 16 0.2× 76 391
Hongfu Cai China 13 266 1.0× 181 0.9× 78 0.8× 144 1.7× 43 0.6× 52 430
Hiroya Taniguchi Japan 14 232 0.9× 180 0.9× 103 1.0× 144 1.7× 67 0.9× 51 539
Naimish Pandya United States 10 226 0.9× 78 0.4× 199 2.0× 44 0.5× 80 1.1× 20 473

Countries citing papers authored by Seiichiro Mitani

Since Specialization
Citations

This map shows the geographic impact of Seiichiro Mitani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seiichiro Mitani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seiichiro Mitani more than expected).

Fields of papers citing papers by Seiichiro Mitani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Seiichiro Mitani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seiichiro Mitani. The network helps show where Seiichiro Mitani may publish in the future.

Co-authorship network of co-authors of Seiichiro Mitani

This figure shows the co-authorship network connecting the top 25 collaborators of Seiichiro Mitani. A scholar is included among the top collaborators of Seiichiro Mitani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Seiichiro Mitani. Seiichiro Mitani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kodama, Hiroko, Yukiya Narita, Michio Nakamura, et al.. (2025). A multicenter, prospective, observational study of nivolumab readministration for advanced gastric cancer (NIVO RETURNS). Future Oncology. 21(14). 1753–1759.
2.
Maron, Steven B., Keisho Chìn, Fadi S. Braiteh, et al.. (2025). Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancers. ESMO Open. 10(11). 105806–105806.
3.
Mitani, Seiichiro, et al.. (2025). Prognostic impact of gene alterations via homologous recombination DNA repair gene alteration status in pancreatic ductal adenocarcinoma. Frontiers in Medicine. 12. 1570731–1570731. 1 indexed citations
4.
Satake, Hirofumi, Shogen Boku, Seiichiro Mitani, et al.. (2024). 10P A placebo-controlled study comparing doses and efficacy of lentinula edodes mycelia for chemotherapy-induced peripheral neuropathy in colorectal cancer: The LEMON trial. Annals of Oncology. 35. S6–S7. 1 indexed citations
5.
Velasco, Marco A. De, et al.. (2024). A machine learning-based method for feature reduction of methylation data for the classification of cancer tissue origin. International Journal of Clinical Oncology. 29(12). 1795–1810.
6.
Muro, Kei, Keisho Chìn, Steven B. Maron, et al.. (2024). Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202.. Journal of Clinical Oncology. 42(16_suppl). 4046–4046. 2 indexed citations
7.
Kito, Yosuke, Hisato Kawakami, Seiichiro Mitani, et al.. (2023). Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G). The Oncologist. 29(3). e330–e336. 5 indexed citations
8.
Kurosaki, Takashi, Kenji Chamoto, Shinichiro Suzuki, et al.. (2023). The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study. Frontiers in Immunology. 14. 1325462–1325462. 12 indexed citations
9.
Mitani, Seiichiro, Yosuke Kito, Kentaro Kawakami, et al.. (2023). Real-World Treatment Sequencing in Vulnerable Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Study. Targeted Oncology. 18(5). 707–715. 2 indexed citations
10.
Otani, Tomoyuki, Masatomo Kimura, Seiichiro Mitani, et al.. (2022). Yolk Sac Tumor in a Recurrence of Colonic Adenocarcinoma With Shared Mutations in APC and TP53 Genes: A Case Report. International Journal of Surgical Pathology. 30(6). 646–651.
11.
12.
Mitani, Seiichiro, Hisato Kawakami, Osamu Shiraishi, et al.. (2022). Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma. Esophagus. 20(2). 281–289. 1 indexed citations
13.
Mitani, Seiichiro, Ken Kato, Hiroyuki Daiko, et al.. (2022). Second primary malignancies in patients with clinical T1bN0 esophageal squamous cell carcinoma after definitive therapies: supplementary analysis of the JCOG trial: JCOG0502. Journal of Gastroenterology. 57(7). 455–463. 4 indexed citations
14.
Yamamoto, Shun, Kengo Nagashima, Takeshi Kawakami, et al.. (2021). Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer. BMC Cancer. 21(1). 1159–1159. 1 indexed citations
15.
Hayashi, Kaori, Seiichiro Mitani, Hiroya Taniguchi, et al.. (2018). Panitumumab Provides Better Survival Outcomes Compared to Cetuximab for Metastatic Colorectal Cancer Patients Treated with Prior Bevacizumab within 6 Months. Oncology. 96(3). 132–139. 2 indexed citations
16.
Hasegawa, Hiroko, Masashi Ando, Yasushi Yatabe, et al.. (2018). Site-specific Chemotherapy Based on Predicted Primary Site by Pathological Profile for Carcinoma of Unknown Primary Site. Clinical Oncology. 30(10). 667–673. 9 indexed citations
17.
Sugiyama, Keiji, Yukiya Narita, Seiichiro Mitani, et al.. (2018). Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer. Anticancer Research. 38(10). 5859–5866. 48 indexed citations
18.
Honda, Kazunori, Bishal Gyawali, Masashi Ando, et al.. (2018). A prospective survey of comprehensive score for financial toxicity in Japanese cancer patients: report on a pilot study. ecancermedicalscience. 12. 847–847. 43 indexed citations
19.
20.
Taniguchi, Hiroya, Yosuke Kito, Satoshi Hamauchi, et al.. (2015). 169P Serum CA19-9 response is an early predictive marker for the efficacy of regorafenib in refractory metastatic colorectal cancer. Annals of Oncology. 26. ix42–ix42.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yukiya Narita Breakdown of academic impact, for papers by Guy de Laroche Breakdown of academic impact, for papers by Frédéric Fiteni Breakdown of academic impact, for papers by Danila Comandini Breakdown of academic impact, for papers by V.E.P.P. Lemmens Breakdown of academic impact, for papers by Olumide B. Gbolahan Breakdown of academic impact, for papers by Jacopo Giuliani Breakdown of academic impact, for papers by Hongfu Cai Breakdown of academic impact, for papers by Hiroya Taniguchi Breakdown of academic impact, for papers by Naimish Pandya
Rankless by CCL
2026